Physician profile
Gregory M Jones
NPI 1366484362
$6,500.64
in general payments reported to CMS, 2019-2025
38 companies · $765 in 2025
The $765 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,336 · 2020: $835 · 2021: $1,932 · 2022: $326 · 2023: $122 · 2024: $183 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $984.79 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $781.69 | 2019-2025 | Airsupra, Breztri |
| Abbvie INC. | $438.30 | 2021-2022 | |
| Pfizer INC. | $428.02 | 2019-2021 | |
| Axsome Therapeutics, INC. | $273.00 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $270.84 | 2019-2021 | |
| Lilly USA, LLC | $259.13 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $235.76 | 2020-2025 | Rybelsus, Ozempic |
| Mannkind Corporation | $192.57 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $179.34 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $165.42 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $152.03 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $146.29 | 2021-2022 | |
| Dexcom, INC. | $143.30 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $139.96 | 2019-2025 | Austedo Xr |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.